Compound III Antipsychotic Treatment Relapse Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for schizophrenia spectrum and other psychotic disorders, including schizophrenia, psychosis, and related conditions, are inadequate as they often result in relapses and significant psychiatric worsening, with existing antipsychotics failing to eradicate symptoms in most patients and causing adverse events.
Innovation Solution
Compound III, a drug substance, is used to treat schizophrenia spectrum and other psychotic disorders, including first episodes and relapses, by reducing psychiatric adverse events and suicidal ideation, and is administered in combination with other antipsychotic drugs to stabilize and prevent disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antipsychotic treatments are used, then psychotic symptoms are dampened, but relapse rates exceed 80% within five years and symptoms are not eradicated
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of antipsychotic compounds (creating compound III with specific molecular configuration) to achieve improved clinical outcomes. The new compound demonstrates enhanced efficacy with reduced relapse rates compared to conventional antipsychotics, transforming the therapeutic parameter profile through structural modification.
Solution Approach 2:
The patent employs composite materials by formulating compound III in combination with other antipsychotic drugs (such as risperidone, olanzapine, or quetiapine) to create a synergistic therapeutic regimen. This composite approach leverages the complementary mechanisms of action between compound III and established antipsychotics to achieve superior and more sustained symptom control.
2Loss of time
If treatment is initiated late in the course of schizophrenia, then intervention occurs, but outcomes remain poor due to delayed reversal of established disease
Solution Approach 1:
The patent applies preliminary action by enabling earlier detection and treatment of psychotic disorders through the use of compound III, which demonstrates efficacy in reducing relapse rates and stabilizing symptoms. The compound allows for intervention before complete disease establishment, preventing progression to chronic schizophrenia and improving long-term outcomes.
3Productivity
If multiple relapses occur in schizophrenia patients, then healthcare costs triple in the following year, but long-term outcomes deteriorate further
Solution Approach 1:
The patent applies continuity of useful action by implementing maintenance therapy with compound III that prevents relapses and maintains continuous symptom control. The compound sustains therapeutic effects over extended periods, preventing the cyclical pattern of relapse and recovery that drives up healthcare costs and worsens long-term prognosis.
4Reliability
If compound III is administered to treat psychotic disorders, then psychiatric adverse events and relapse rates decrease, but the compound requires combination with other antipsychotics for optimal effect
Solution Approach 1:
The patent applies merging by combining compound III with established antipsychotic medications to create an enhanced therapeutic regimen. This combination leverages the unique mechanism of compound III (reducing relapse and adverse events) with the proven efficacy of conventional antipsychotics, achieving synergistic effects that outweigh the increased regimen complexity.
Data Source
AI summary
The present invention relates to compound IIIand its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.